7-OH: Emergence of a Fourth Opioid Epidemic
Similar Posts
FDA | NIH : Regulatory Do’s and Don’ts: Tips from FDA – 09/04/2024
FDA | NIH : Regulatory Do’s and Don’ts: Tips from FDAPatent Certifications and Suitability Petitions
Information on patents and suitability petitions that impact the availability of generic drugs.Doan’s Bakery Issues Allergy Update on Undeclared Wheat and Milk Allergens in Bundt Cakes
Doan’s Bakery of Woodland Hills, CA is recalling White Chocolate Coconut and Carrot Bundt Cakes because they may contain undeclared wheat and milk. People who have an allergy or severe sensitivity to wheat and/or milk run the risk of experiencing a serious or life-threatening reaction if they consumPublic Meeting on the Reauthorization of the Prescription Drug User Fee Act (PDUFA) – 07/14/2025
On July 14, 2025, the Food and Drug Administration (FDA or Agency) held a public meeting to discuss proposed recommendations for the reauthorization of the Prescription Drug User Fee Act (PDUFA) for fiscal years (FYs) 2028 through 2032.List of Off-Patent, Off-Exclusivity Drugs without an Approved Generic
The FDA maintains a list of approved new drug application (NDA) drug products that are no longer protected by patents or exclusivities, and for which the FDA has not approved an ANDA referencing that NDA drug product.Power Plus Desire contains hidden drug ingredient
The Food and Drug Administration is advising consumers not to purchase or use Power Plus Desire, a product promoted and sold for sexual enhancement on various websites and possibly in some retail stores.